Piper Sandler lowers Arbor Realty Trust stock price target on credit issues
Investing.com - Cantor Fitzgerald raised its price target on Ventas (NYSE:VTR) to $85.00 from $77.00 on Friday, while maintaining an Overweight rating on the healthcare real estate investment trust. The new target represents a potential 14.4% upside from Ventas’s current price of $74.27. InvestingPro data shows VTR is trading near its 52-week high of $74.71, after delivering an impressive 29.03% return year-to-date.
The price target increase represents approximately a 28x multiple on Cantor Fitzgerald’s 2026 estimated adjusted funds from operations (AFFO) for the company.
According to Cantor Fitzgerald, Ventas currently trades at 25 times FactSet consensus 2026 estimated AFFO and at a 30% premium to FactSet consensus net asset value (NAV).
The firm noted that potential risks to achieving the new price target include any signs of stalling growth in the Senior Housing segment, which has been a key driver for Ventas.
Cantor Fitzgerald also highlighted that exposure to Life Science properties, while representing only 8% of Ventas’s portfolio, "remains a relative question market versus the outsized growth of Senior Housing."
In other recent news, Ventas Inc . reported its third-quarter 2025 earnings, surpassing analyst expectations. The company achieved an earnings per share (EPS) of $0.14, which was higher than the forecasted $0.09, representing a 55.56% surprise. Additionally, Ventas reported revenue of $1.49 billion, exceeding the anticipated $1.44 billion. These results highlight a strong performance for the quarter. There were no recent reports of mergers or acquisitions involving Ventas. Analyst notes regarding upgrades or downgrades of the stock were not mentioned in the recent updates. The company’s stock price movement was noted following the earnings announcement, but specific figures related to stock performance are not covered in this article.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.
